Vaccine efficacy based on 2 doses: Bharat Biotech after Vij tests positive

Covaxin is an indigenously developed Covid-19 vaccine undergoing a trial on over 26,000 people across 25 sites in India to evaluate the efficacy of the vaccine candidate

After Haryana minister Anil Vij, who is a participant in the phase 3 clinical trial of Bharat Biotech's investigational Covid19 vaccine candidate, tested positive for the Sars-CoV-2 virus, the Hyderabad based vaccine maker clarified that Covaxin has been designed to be efficacious based on a two-dose schedule, given 28-days apart.

The company also clarified that the vaccine efficacy will be determined 14-days post the second dose. Further, Bharat Biotech International (BBIL) said that the phase 3 trials are double blinded and randomised where 50 per cent of the subjects will receive the vaccine, and 50 per cent would receive the